Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ONCY Stock Forecast 2025-2026
$0.51
Current Price
$44.96M
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ONCY Price Targets
+898.0%
To High Target of $5.13
+700.0%
To Median Target of $4.12
+501.9%
To Low Target of $3.10
ONCY Price Momentum
-7.3%
1 Week Change
-17.7%
1 Month Change
-56.4%
1 Year Change
-44.0%
Year-to-Date Change
-66.4%
From 52W High of $1.53
+9.5%
From 52W Low of $0.47
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Oncolytics (ONCY) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ONCY and similar high-potential opportunities.
Latest ONCY Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, ONCY has a bullish consensus with a median price target of $4.12 (ranging from $3.10 to $5.13). Currently trading at $0.51, the median forecast implies a 700.0% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ONCY Analyst Ratings
7
Buy
0
Hold
0
Sell
ONCY Price Target Range
Low
$3.10
Average
$4.12
High
$5.13
Current: $0.51
Latest ONCY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ONCY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 10, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Mar 10, 2025 | RBC Capital | Douglas Miehm | Outperform | Maintains | $5.00 |
| Mar 10, 2025 | Maxim Group | Jason McCarthy | Buy | Maintains | $3.00 |
| Feb 3, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Sep 19, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Aug 21, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| May 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Apr 4, 2024 | Raymond James | Rahul Sarugaser | Outperform | Initiates | $3.00 |
| Mar 8, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $5.00 |
| Feb 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Jan 19, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Jan 4, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Nov 13, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $5.00 |
| Aug 16, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $15.00 |
| Jun 29, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $15.00 |
| Jun 23, 2023 | Canaccord Genuity | John Newman | Buy | Reiterates | $5.00 |
| Jun 7, 2023 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| May 26, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $15.00 |
| May 24, 2023 | JonesTrading | Soumit Roy | Buy | Initiates | $9.00 |
Oncolytics Biotech Inc. (ONCY) Competitors
The following stocks are similar to Oncolytics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Oncolytics Biotech Inc. (ONCY) Financial Data
Oncolytics Biotech Inc. has a market capitalization of $44.96M with a P/E ratio of -1.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -189.1%.
Valuation Metrics
Market Cap
$44.96M
Enterprise Value
$22.79M
P/E Ratio
-1.3x
PEG Ratio
-1.7x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+35.8%
Current Ratio
2.8x
Debt/Equity
17.8x
ROE
-189.1%
ROA
-74.1%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Oncolytics Biotech Inc. (ONCY) Business Model
About Oncolytics Biotech Inc.
What They Do
Develops innovative cancer therapeutics using viruses.
Business Model
Oncolytics Biotech Inc. operates within the biotech sector, focusing on the development of pelareorep, an immuno-oncolytic virus. The company makes money by advancing clinical trials and securing partnerships or collaborations that may lead to commercialization of its therapies, particularly for cancers resistant to traditional treatments.
Additional Information
As a development-stage company, Oncolytics Biotech is actively engaged in research and innovation, positioning itself as a pioneer in the oncology field. Its work has the potential to significantly improve patient outcomes and expand treatment options in cancer care.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
29
CEO
Dr. Matthew C. Coffey M.B.A., Ph.D.
Country
Canada
IPO Year
2018
Website
www.oncolyticsbiotech.comOncolytics Biotech Inc. (ONCY) Latest News & Analysis
Latest News
Quick Summary
Oncolytics Biotech Inc. will host a conference call and webcast on May 14, 2025, at 4:30 p.m. ET. The company focuses on immunotherapy for oncology.
Why It Matters
The scheduled conference call may reveal key updates on Oncolytics Biotech's progress and strategy, impacting stock performance and investor sentiment in the oncology sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Oncolytics Biotech will present new data on pelareorep's efficacy in pancreatic cancer at the ASCO Annual Meeting from May 30 to June 3, 2025, highlighting its potential in challenging treatments.
Why It Matters
Positive data on pelareorep's efficacy in treating pancreatic cancer could boost Oncolytics Biotech's stock, indicating potential for breakthrough therapies in a challenging market segment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Oncolytics Biotech Inc. (NASDAQ: ONCY, TSX: ONC) was featured by key opinion leaders at a recent H.C. Wainwright event, highlighting its focus on immunotherapy for oncology.
Why It Matters
Key opinion leader discussions can enhance credibility and interest in Oncolytics Biotech's immunotherapy, potentially influencing stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Oncolytics Biotech Inc. (NASDAQ: ONCY) has signed a share purchase agreement with Alumni Capital LP, securing funding to advance its immunotherapy pelareorep and minimize shareholder dilution.
Why It Matters
Oncolytics Biotech's funding partnership with Alumni Capital enhances financial stability, supports clinical progress, and reduces dilution, potentially boosting shareholder value and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Oncolytics Biotech Inc. (NASDAQ:ONCY) will hold a Q4 2024 results conference call on March 7, 2025, at 8:30 AM ET, featuring key executives and analysts from Raymond James and H.C. Wainwright.
Why It Matters
The upcoming conference call will provide insights into Oncolytics Biotech's financial performance and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Oncolytics Biotech reported positive BRACELET-1 results in HR+/HER2- metastatic breast cancer, with ongoing studies in pancreatic and anal carcinoma. They have $15.9 million cash, funding through Q3 2025.
Why It Matters
Positive clinical results for Oncolytics Biotech's therapies may boost investor confidence, influencing stock performance. Strong cash reserves extend operational stability into 2025, critical for ongoing studies.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ONCY Stock
What is Oncolytics Biotech Inc.'s (ONCY) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Oncolytics Biotech Inc. (ONCY) has a median price target of $4.12. The highest price target is $5.13 and the lowest is $3.10.
Is ONCY stock a good investment in 2025?
According to current analyst ratings, ONCY has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.51. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ONCY stock?
Wall Street analysts predict ONCY stock could reach $4.12 in the next 12 months. This represents a 700.0% increase from the current price of $0.51. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Oncolytics Biotech Inc.'s business model?
Oncolytics Biotech Inc. operates within the biotech sector, focusing on the development of pelareorep, an immuno-oncolytic virus. The company makes money by advancing clinical trials and securing partnerships or collaborations that may lead to commercialization of its therapies, particularly for cancers resistant to traditional treatments.
What is the highest forecasted price for ONCY Oncolytics Biotech Inc.?
The highest price target for ONCY is $5.13 from at , which represents a 898.0% increase from the current price of $0.51.
What is the lowest forecasted price for ONCY Oncolytics Biotech Inc.?
The lowest price target for ONCY is $3.10 from at , which represents a 501.9% increase from the current price of $0.51.
What is the overall ONCY consensus from analysts for Oncolytics Biotech Inc.?
The overall analyst consensus for ONCY is bullish. Out of 7 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.12.
How accurate are ONCY stock price projections?
Stock price projections, including those for Oncolytics Biotech Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2025 4:21 PM UTC